Epidemiology of Hepatitis B in Central and Eastern Europe | Adrian Streinu Cercel, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Management of Drug Drug Interactions | David Back, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

An Integrated Approach to HCV Treatment in People who Inject Drugs Cross Europe | Mojca Maticic, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

State of the Art Treatment of HCV | Sanjay Bhagani, BSc FRCP

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Management of End-stage Liver Disease | Massimo Puoti, MD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Natural History of HCV Infection | Krzysztof Simon, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Turkey | Cihan Yurdaydin, MD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Czech and Slovak Republics | Viktor Aster, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Baltic Countries | Saulius Caplinskas, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Romania | Adrian Streinu Cercel, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Ukraine | Larisa Moroz, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Poland | Milosz Parczewski, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Perspective from Medical Community | Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD

International Hepatitis Cure & Eradication Meeting 2015

Perspective from health economics | David Rein, PhD

International Hepatitis Cure & Eradication Meeting 2015

Session 4 Roundtable discussion

International Hepatitis Cure & Eradication Meeting 2015

Rational pricing and the role of generics | Raymond Schinazi, PhD, DSc

International Hepatitis Cure & Eradication Meeting 2015

Hepatitis C treatment | Manal El-Sayed, MD, PhD

International Hepatitis Cure & Eradication Meeting 2015

Perspective from Payers | Mel Krajden, MD, FRCPC

International Hepatitis Cure & Eradication Meeting 2015

Perspective from Payers | Bonnie Henry, MD, MPH, FRCPC

International Hepatitis Cure & Eradication Meeting 2015

Maximizing SVR with current HCV therapy | Alnoor Ramji, MD, FRCP

International Hepatitis Cure & Eradication Meeting 2015

New Treatment in HCV: Is there need for more therapies? | Jordan Feld, MD, MPH

International Hepatitis Cure & Eradication Meeting 2015

New Treatment Strategies for Hepatitis B | Harry Janssen, MD, PhD

International Hepatitis Cure & Eradication Meeting 2015

New tools for testing and monitoring Hepatitis B and C | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

International Hepatitis Cure & Eradication Meeting 2015

Baby Boomer Screening in the U.S: Delivering on the promise thus far? | John Ward, MD

International Hepatitis Cure & Eradication Meeting 2015